Prognostic significance of elevated serum CD44 levels in patients with oral squamous cell carcinoma. (8th June 2018)

• Record Type: Journal Article
• Authors: Sawant, Sharada; Ahire, Chetan; Dongre, Harsh; Joshi, Shriya; Jamghare, Sayli; Rane, Pallavi; Kane, Shubhada; Chaukar, Devendra
• Is Part Of: Journal of oral pathology & medicine. Volume 47:Number 7(2018)
• Page Start: 665
• Page End: 673
• Publication Date: 2018-06-08
• Subjects: CD44v6 expression -- locoregional recurrence -- oral squamous cell carcinoma -- prognostic marker -- serum CD44 levels; Dentistry -- Periodicals; Teeth -- Diseases -- Periodicals; 617
• DOI: 10.1111/jop.12731
• Languages: English
• ISSNs: 0904-2512

Abstract

Abstract : Background: Availability of reliable methods distinguishing high‐risk recurrent tumours from regressive tumours prior to surgery could help in better management of the disease. This study was aimed to estimate pre‐surgical serum CD44 concentration and assess the possibility of using it as a non‐invasive prognostic tool in oral cancer. Methods: ELISA was performed on pre‐surgical serum samples from 64 primary oral cancer patients and 16 healthy individuals to estimate soluble CD44 levels. Immunohistochemistry was performed on parallel 64 solid tumours and 10 recurrent tumours. All patients clinically followed up for median period of 19.2 months and obtained prognostic information correlated with CD44 concentration in serum as well as in tumours. Results: Serum CD44 concentration was found significantly high in patients as compared to healthy individuals ( P < .001) and also in patients whose disease locally recurred as compared to those did not recur ( P = 0026). High serum CD44 concentration inversely affected on patients survival ( P = .032). CD44v6 staining intensity was detected significantly high in recurrent tumours as compared to primary tumours ( P < .001), and it also correlated with poor survival ( P < .001). Furthermore, in combination, patients with increased CD44 concentration in serum and CD44v6 expression in tumours significantly correlated with local recurrence ( P < .001) and poor survival ( P < .001). Conclusion: Our data suggest that the ELISA‐based estimation of pre‐surgical serum CD44 concentration could be a non‐invasive reliable method distinguishing high‐risk recurrent tumours which can further assist in post‐surgery treatment planning.